Dolasteron
Dolasteron - General Information
Dolasteron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasteron is a highly specific and selective serotonin 5-HT3 receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors.
Pharmacology of Dolasteron
Dolasteron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasteron is a highly specific and selective serotonin 5-HT3 receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors.
Dolasteron for patients
Patient Information:
Discuss about the side effects with your doctor before taking dolasetron. Let the doctor know about the
medications you are taking and you medical conditions.
Do not change dose or dosing schedule without consulting your doctor.
Dolasteron Interactions
The potential for clinically significant drug-drug interactions posed by dolasetron and hydrodolasetron appears to be low for drugs commonly used in chemotherapy or surgery, because hydrodolasetron is eliminated by multiple routes. Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.
Dolasetron has been safely coadministered with drugs used in chemotherapy and surgery. As with other agents which prolong ECG intervals, caution should be exercised in patients taking drugs which prolong ECG intervals, particularly QTc.
In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron. Clearance of hydrodolasetron decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with atenolol. Dolasetron does not influence anesthesia recovery time in patients. Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, 5-fluorouracil, doxorubicin, cyclophosphamide) in four murine models.
Dolasteron Contraindications
ANZEMET Tablets are contraindicated in patients known to have hypersensitivity to the drug.
Additional information about Dolasteron
Dolasteron Indication: For the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy, including initial and repeat courses and prevention of postoperative nausea and vomiting
Mechanism Of Action: Dolasteron is a selective serotonin 5-HT3 receptor antagonist. The serotonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine, and that the released serotonin then activates 5-HT3 receptors located on vagal efferents to initiate the vomiting reflex. Therefore Dolasteron works by blocking the reception of serotonin at these 5-HT3 receptors.
Drug Interactions: Not Available
Food Interactions: Take without regard to meals.
Generic Name: Dolasetron
Synonyms: Not Available
Drug Category: Antiemetics; Serotonin Antagonists
Drug Type: Small Molecule; Approved
Other Brand Names containing Dolasetron: Anzemet; Dolasetronum [Inn-Latin]; Dolasteron;
Absorption: Orally-administered dolasetron is well absorbed
Toxicity (Overdose): Not Available
Protein Binding: 69-77%
Biotransformation: Hepatic
Half Life: 8.1 hours
Dosage Forms of Dolasteron: Solution Intravenous
Tablet Oral
Chemical IUPAC Name: Not Available
Chemical Formula: C19H20N2O3
Dolasetron on Wikipedia: https://en.wikipedia.org/wiki/Dolasetron
Organisms Affected: Humans and other mammals
